Client Ramius Offers to Acquire Therapeutic Drugmaker for $154M

Firm News

Olshan's client Ramius LLC offered to buy drugmaker Cypress Bioscience Inc. for approximately $154 million and asked the board to abstain from approving any further acquisitions. Ramius currently holds a 9.9% stake in Cypress. The Wall Street Journal (subscription required) and Forbes, among other media, reported on the story.

Steve Wolosky, Andrew M. Freedman, Amanda S. Lamson, and Michael D. DeDonato with litigation assistance from Thomas J. Fleming comprise the Olshan team representing Ramius.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.